Concepedia

Ying Huang

YH

3

Publications

58

Citations

3

H-Index

2023

Active since

Affiliations

University of Maryland, Baltimore(Current)

U-M Rogel Cancer Center

Oregon Health & Science University

University of North Carolina at Chapel Hill

Memorial Sloan Kettering Cancer Center

Ying Huang is an author at University of Maryland, Baltimore specializing in clinical trials, molecular oncology, and combination therapy.

ORCID

Top concepts

Publications per year

2023–2025

3

Publications

3

Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

Fieke W. Hoff, William Blum, Ying Huang et al. · Blood Advances · 2024 · 21 citations · Full text

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed <i>IDH2</i>-mutant AML

Sheng F. Cai, Ying Huang, Jennie Rachel Lance et al. · Blood Advances · 2023 · 19 citations · Full text

, , +18

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML

Joshua F. Zeidner, Tara L. Lin, Rina Li Welkie et al. · Journal of Clinical Oncology · 2025 · 18 citations · Full text

Rows per page

1–3 of 3